Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancers.

Science advances - 5 Jun 2026

Kim Jiwon, Oh Jaeik, Jang Dongjun, Shin Seungjae, Lee Soo-Jin, Lee Sang Eun, Yang Yoojin, Kim Dohee, Choi Ae Jin, Jung Hae Rim, Oh Yumi, Cho Sung-Yup

Abstract excerpt

ARID1A (AT-rich interaction domain 1A), a key subunit of the switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex, is frequently mutated in cancers. However, effective clinical treatments for patients with this mutation are limited, highlighting a need for therapeutic strategies. Here, we identify Werner syndrome adenosine 5'-triphosphate-dependent helicase (WRN) as a critical vulnerability in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Checkpoint Kinase 1
Share to Checkpoint Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p21

Share to DNA Damage

Share to Enzyme Inhibitors

Share to Molecular Targeted Therapy

Share to Werner Syndrome Helicase

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 42247504
DOI: 10.1126/sciadv.aeb3726
PMCID: PMC13240190

Genes

ARID1A
WRN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancers.PMID 42247504Read ↗

Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancersSemantic proximity Read ↗

Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cellsSemantic proximity Read ↗

The Werner syndrome RECQ helicase as a therapeutic target: new insights.Semantic proximity Read ↗

Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cellsSemantic proximity Read ↗

The Role of the AT-Rich Interaction Domain 1A Gene (ARID1A) in Human Carcinogenesis.Semantic proximity Read ↗

Potential therapeutic targets in ARID1A-mutated cancers.Semantic proximity Read ↗

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsSemantic proximity Read ↗

Therapeutic Role of Synthetic Lethality in ARID1A -Deficient MalignanciesSemantic proximity Read ↗

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor TherapySemantic proximity Read ↗

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1ASemantic proximity Read ↗

Targeting the Werner syndrome protein in microsatellite instability cancers: mechanisms and therapeutic potentialSemantic proximity Read ↗

Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.